Ophthalmology

Bausch + Lomb Announces Key Leadership Changes

Retrieved on: 
Thursday, June 1, 2023
Medical Supplies, Medical Devices, Health, Surgery, Pharmaceutical, Optical, EVP, Bausch & Lomb, Growth, Ophthalmology, SVP, Patient, NYSE, Schonfeld Strategic Advisors, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads.
  • Additionally, Louis Yu, Ph.D., executive vice president (EVP) and Chief Quality Officer, has notified Bausch + Lomb of his intent to retire later this summer, and the Company will commence an internal and external search for his replacement.
  • With these changes to the executive management team, our leaders will be closer to customers and patients, which will set the stage for accelerated growth and propel Bausch + Lomb toward a highly competitive, efficient and effective future,” said Saunders.
  • “The next chapter of Bausch + Lomb is built upon the efforts of the strong business unit leadership we’ve had for the past several years.”
    “I’d also like to express my deep gratitude to Joe Gordon and Louis Yu.

Dr. Deepika Malik: A Leading Vitreoretinal Surgeon Joins OCLI Vision, Offering Exceptional Eye Care Services

Retrieved on: 
Thursday, June 1, 2023
Faculty, Learning, Retinal detachment, Branch retinal vein occlusion, University, American Board of Ophthalmology, Associate professor, University of California, Irvine Medical Center, Philadelphia College of Osteopathic Medicine, Hindi, American Academy, Drexel University College of Medicine, Retina, Research, American Medical Association, Public key certificate, Osteopathy, American Board of Commissioners for Foreign Missions, MD, Patient, Diabetic retinopathy, SVP, Society, Nursing, Medical device, Ophthalmology

MINEOLA, N.Y., June 1, 2023 /PRNewswire-PRWeb/ -- Deepika Malik, MD, a highly experienced and fellowship-trained vitreoretinal surgeon, is ecstatic to join the OCLI Vision team, offering expert eye care services to patients in Rockland County, Orange County, and the boroughs of Queens, Manhattan, and Brooklyn. With her expertise in macular disorders, including age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, inflammatory ocular diseases, and surgical retinal diseases, Dr. Malik has built a well-respected name in the realm of ophthalmology.

Key Points: 
  • OCLI Vision, a Spectrum Vision Partners (SVP) managed practice, has announced the addition of Deepika Malik, MD, an esteemed Vitreoretinal Surgeon with experience spanning 15 years .
  • Dr. Malik is a Diplomate of the American Board of Ophthalmology and is Board Certified in Ophthalmology.
  • She completed her surgical vitreoretinal fellowship at Gavin Herbert Eye Institute at the University of California, Irvine.
  • With Dr. Malik's expert care, patients can trust that their eye health is in great hands.

Aequus Provides General Update and First Quarter 2023 Financial Highlights

Retrieved on: 
Wednesday, May 31, 2023
Acceleration, KOL, Partnership, Tacrolimus, Optometry, OTCQB, Research, AQS, HCP, Sale, Ophthalmology, CRM, Pharmaceutical industry, Novartis, Q1

VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments.

Key Points: 
  • VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments.
  • “As anticipated, revenues for the quarter were reduced due to the completion of the Sandoz contract at the end of last year.
  • Aequus recorded a net loss of $744,323 for the three months ended March 31, 2023, which is 19% lower than the loss of $916,886 for the period ending March 31, 2022.
  • The Company realized a 132% increase in Evolve product sales during the three months ended March 31, 2023, relative to the prior year.

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Retrieved on: 
Wednesday, May 31, 2023
Optical coherence tomography, Retina, PDE6B, Eye, Retinitis pigmentosa, Visual impairment, Visual field, Paratriathlon, Doctor of Philosophy, CNS, Associate, Central nervous system, Patient, OCT, Microperimetry, Mobility, Ageing, Phase, Therapy, Disease, Safety, Pharmaceutical industry, Medical imaging, Ophthalmology, MD

These positive data support Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.

Key Points: 
  • These positive data support Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.
  • To date, CTx-PDE6b has been administered to 17 patients aged 18 years and older presenting an advanced form of PDE6b RP using two ascending doses.
  • The treatment was administered in the more affected eye while the other eye served as an untreated control.
  • “We are highly encouraged by the safety and efficacy data observed so far in patients who have been treated with CTx-PDE6b.

Todd Lehman Joins LumaBridge as Vice President and Head of Business Development

Retrieved on: 
Wednesday, May 31, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PPD, Business development, Laboratory, Medical Affairs Bureau, University, Clinical trial, Thermo Fisher Scientific, Biomedical engineering, Alcon, Chemical engineering, Ophthalmology, Growth, Therapy, Fine chemical

LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.

Key Points: 
  • LumaBridge, a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, today announced the appointment of Todd Lehman as Vice President and Head of Business Development.
  • Todd brings nearly 20 years of client services, commercial and clinical operations experience to LumaBridge.
  • "We are thrilled to welcome Todd to the LumaBridge team," said David Boyle, Chief Executive Officer of LumaBridge.
  • “I’m honored to be joining LumaBridge at this exciting stage of growth in the company’s evolution,” said Todd Lehman.

Thea Pharma Inc. Launches Preservative Freedom Coalition to Advocate for Preservative-free Eye Care

Retrieved on: 
Tuesday, May 30, 2023
Real, Habit, Education, OD, Coalition, Eye, Ophthalmology, Indifference, Apathy, MD, Patient, OTC, Health, Environment, Nursing, Thea

WALTHAM, Mass., May 30, 2023 /PRNewswire/ -- Thea Pharma Inc. ("Thea"), the U.S. subsidiary of Europe's leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet needs in ocular surface disease and opportunities to pursue preservative-free topical ophthalmic medications. In addition to Thea, founding members of this company- and brand-agnostic initiative include: The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology.

Key Points: 
  • The Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.
  • "The eye care industry has a long history of using preservatives in eye drops that persists to this day.
  • "The Preservative Freedom Coalition has the potential to make a significant impact on the education of the entire eye care community and to elevate the awareness of the deleterious effect of preservatives on the ocular surface."
  • "We look forward to working with colleagues across the ophthalmologic, optometric, medical, and pharmaceutical communities as part of the Preservative Freedom Coalition to achieve this shared vision."

BNS and RAFARM create BNS Ophthalmics to leverage nanotechnology in the development of novel ophthalmic products

Retrieved on: 
Tuesday, May 30, 2023
Transfer, Hebrew University of Jerusalem, Cornea, Partnership, BNS, Macular edema, Tacrolimus, IP, Telecanthus, Patient, Water, FDA, BNSO, Nanotechnology, Safety, Pharmaceutical industry, Ophthalmic, Ophthalmology

BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.

Key Points: 
  • BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim to address serious ophthalmic unmet needs for patients around the world.
  • BNS will contribute its intellectual property and R&D expertise to BNSO while Rafarm will provide appropriate funding, together with infrastructure for development, commercial scale manufacturing, and distribution.
  • Our collaboration with BNS, whom we recognize as a leader in the field of nanotechnology, marks a significant milestone of RAFARM in innovative technologies.
  • We join forces with BNS for the development and production of novel therapeutic products and to further expand our expertise in ophthalmics."

BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases

Retrieved on: 
Tuesday, May 30, 2023
Retina, Harvard University, Research, Weizmann Institute of Science, TEL, Ophthalmology, TASE, Tel Aviv Sourasky Medical Center, Invention, Alexion, Diagnosis, Paratriathlon, Pharmaceutical industry

The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes components of the tear film, an outer eye surface fluid layer.

Key Points: 
  • The study, financed by Alexion and BioLight, will evaluate a screening technique (the "Technology") that analyzes components of the tear film, an outer eye surface fluid layer.
  • Early detection and treatment in the preliminary stages of retinal eye disease can prevent vision loss for a significant number of people.
  • Finding an effective and simple tool for diagnosing during the early stages of the disease's development is a game changer.
  • This is the objective of the experiment and research, endeavoring to detect retinal disease through human tear sampling," stated Yaacov Michlin, CEO BioLight.

VOFTW Launches Groundbreaking Course on New Canvas Platform, Revolutionizing Veterinary Ophthalmology Education

Retrieved on: 
Thursday, May 25, 2023
Learning, Knowledge, Ophthalmology, Animal, Tutoring, Canvas

Mexico City, Mexico--(Newsfile Corp. - May 24, 2023) - Veterinary Ophthalmology For The World (VOFTW), a leading provider of veterinary education, is proud to announce the launch of its highly anticipated course on veterinary ophthalmology on the new Canvas platform.

Key Points: 
  • Mexico City, Mexico--(Newsfile Corp. - May 24, 2023) - Veterinary Ophthalmology For The World (VOFTW), a leading provider of veterinary education, is proud to announce the launch of its highly anticipated course on veterinary ophthalmology on the new Canvas platform.
  • Dr. Gustavo Adolfo Garcia, a distinguished ACVO Veterinary Ophthalmologist and the mastermind behind the course, is excited to introduce this groundbreaking program.
  • Upon finishing the veterinary ophthalmology course, participants will be awarded a certificate of completion by Dr. Gustavo Adolfo Garcia.
  • For more information about the VOFTW veterinary ophthalmology course, Dr. Gustavo Adolfo Garcia, and the Canvas platform, visit the official website at www.voftw.com .

Revolutionizing Veterinary Ophthalmology Education: VOFTW Launches Groundbreaking Course on New Canvas Platform

Retrieved on: 
Wednesday, May 24, 2023
Certification, Learning, Knowledge, Grassroots Party, Ophthalmology, Animal, Veterinary medicine, Canvas

Mexico City, Mexico--(Newsfile Corp. - May 24, 2023) - Veterinary Ophthalmology For The World (VOFTW), a leading provider of veterinary education, is set to transform the field of veterinary ophthalmology with the launch of its groundbreaking course for the year 2023.

Key Points: 
  • Mexico City, Mexico--(Newsfile Corp. - May 24, 2023) - Veterinary Ophthalmology For The World (VOFTW), a leading provider of veterinary education, is set to transform the field of veterinary ophthalmology with the launch of its groundbreaking course for the year 2023.
  • This platform offers an interactive and user-friendly interface that provides 24/7 access to valuable veterinary ophthalmology content.
  • "I am thrilled to introduce this innovative course on veterinary ophthalmology in collaboration with the Canvas platform," said Dr. Gustavo Adolfo Garcia.
  • To learn more about VOFTW and Dr. Gustavo Adolfo Garcia's veterinary ophthalmology course, interested individuals can visit the official website at www.voftw.com .